Anti-vascular endothelial growth factor therapy for diabetic macular edema

Therapeutic Advances in Endocrinology and Metabolism

Volumn 4, Issue 6, 2013, Pages 151-169

  Boyer, David S ^a   Hopkins, J Jill ^b   Sorof, Jonathan ^b   Ehrlich, Jason S ^b  

^a RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^b GENENTECH INC   (United States)

Author keywords

diabetic macular edema; diabetic retinopathy; intravitreal anti VEGF therapy; vascular endothelial growth factor A

Indexed keywords

AFLIBERCEPT; ATENOLOL; BEVACIZUMAB; CAPTOPRIL; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; INSULIN; NEUROPILIN 1; PEGAPTANIB; RANIBIZUMAB; SULFONYLUREA; TRIAMCINOLONE; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ARTERIAL THROMBOEMBOLISM; BINDING AFFINITY; BLEEDING; CATARACT; CONJUNCTIVAL HEMORRHAGE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FOLLOW UP; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; NONHUMAN; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA NEOVASCULARIZATION; RETINAL THICKNESS; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL PROSTHESIS; WOUND HEALING IMPAIRMENT;

EID: 84890104909     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018813512360     Document Type: Review

References (103)

1. Adamis A. Miller J. Bernal M. D'Amico D. Folkman J. Yeo T. et al. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445–450.
2. Adamis A. Shima D. Tolentino M. Gragoudas E. Ferrara N. Folkman J. et al. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114: 66–71.
3. Adamis A. Shima D. Yeo K. Yeo T. Brown L. Berse B. et al. (1993) Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 193: 631–638.
4. Afzal A. Shaw L. Ljubimov A. Boulton M. Segal M. Grant M. (2007) Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res 74: 131–144.
5. Alimera Sciences (2013) Alimera Sciences announces ILUVIEN® now available in U.K. Available at: http://investor.alimerasciences.com/releasedetail.cfm?ReleaseID=759915 (accessed 12 September 2013).
6. American Academy of Ophthalmology (2008) Preferred practice pattern® guidelines. Available at: http://www.aao.org/ppp (accessed 30 October 2013).
7. American Diabetes Association (2012) Standards of medical care in diabetes – 2012. Diabetes Care 35(Suppl. 1): S11–S63.
8. American Diabetes Association (2013) Economic costs of diabetes in the US in 2012. Diabetes Care 36: 1033–1046.
9. Baffert F. Le T. Sennino B. Thurston G. Kuo C. Hu-Lowe D. et al. (2006) Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290: H547–H559.
10. Bloomgarden Z. (2007) Screening for and managing diabetic retinopathy: current approaches. Am J Health Syst Pharm 64(17, Suppl. 12): S8–S14.
11. Bragge P. Gruen R. Chau M. Forbes A. Taylor H. (2011) Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol 129: 435–444.
12. Brown D. Nguyen Q. Marcus D. Boyer D. Patel S. Feiner L. et al. (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120: 2013-2022.
13. Burditt A. Caird F. Draper G. (1968) The natural history of diabetic retinopathy. Q J Med 37: 303–317.
14. Bursell S. Brazionis L. Jenkins A. (2012) Telemedicine and ocular health in diabetes mellitus. Clin Exp Optom 95: 311–327.
15. Callanan D. Gupta S. Boyer D. Ciulla T. Singer M. Kuppermann B. et al. (2013) Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 120: 1843–1851.
16. Campochiaro P. Brown D. Pearson A. Chen S. Boyer D. Ruiz-Moreno J. et al. (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119: 2125–2132.
17. Campochiaro P. Brown D. Pearson A. Ciulla T. Boyer D. Holz F. et al. (2011) Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 118: 626–635 e2.
18. Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed 15 October 2012).
19. Chakravarthy U. Harding S. Rogers C. Downes S. Lotery A. Wordsworth S. et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119: 1399–1411.
20. Chen H. Cleck J. (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465–477.
21. Crosby M. Shuman V. (2011) Physicians’ role in eye care of patients with diabetes mellitus – are we doing what we need to? J Am Osteopath Assoc 111: 97–101.
22. Cunningham E. Jr Adamis A. Altaweel M. Aiello L. Bressler N. D'Amico D. et al. (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747–1757.
23. Curtis L. Hammill B. Qualls L. DiMartino L. Wang F. Schulman K. et al. (2012) Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries. Am J Ophthalmol 153: 1116–1124.
24. Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44: 968–983.
25. Diabetes Prevention Program Research Group (2007) The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 24: 137–144.
26. Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115: 1447–1459.
27. Diabetic Retinopathy Study Research Group (1987) Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. Int Ophthalmol Clin 27: 239–253.
28. Diabetic Retinopathy Vitrectomy Study Research Group (1985) Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 2. Arch Ophthalmol 103: 1644–1652.
29. Diabetic Retinopathy Vitrectomy Study Research Group (1988) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial – Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology 95: 1307–1320.
30. Do D. Nguyen Q. Boyer D. Schmidt-Erfurth U. Brown D. Vitti R. et al. (2012) One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119: 1658–1665.
31. Do D. Nguyen Q. Khwaja A. Channa R. Sepah Y. Sophie R. et al. (2013) Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 131: 139–145.
32. Do D. Nguyen Q. Shah S. Browning D. Haller J. Chu K. et al. (2009) An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 93: 144–149.
33. Do D. Schmidt-Erfurth U. Gonzalez V. Gordon C. Tolentino M. Berliner A. et al. (2011) The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 118: 1819–1826.
34. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796–1806.
35. Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98(Suppl. 5): 766–785.
36. Elman M. Aiello L. Beck R. Bressler N. Bressler S. Edwards A. et al. (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064–1077.
37. Elman M. Bressler N. Qin H. Beck R. Ferris F. III Friedman S. et al. (2011) Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118: 609–614.
38. Elman M. Qin H. Aiello L. Beck R. Bressler N. Ferris F. III et al. (2012) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119: 2312–2318.
39. Eremina V. Sood M. Haigh J. Nagy A. Lajoie G. Ferrara N. et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707–716.
40. European Medicines Agency (2013) Lucentis: EPAR – all authorized presentations EMEA/H/C/000715 -IAIN/0039. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf (accessed 31 July 2013).
41. Ferrara N. Gerber H. LeCouter J. (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676.
42. Ferrara N. Damico L. Shams N. Lowman H. Kim R. (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859–870.
43. Fong D. Aiello L. Ferris F. III Klein R. (2004) Diabetic retinopathy. Diabetes Care 27: 2540–2553.
44. Frank R. (2004) Diabetic retinopathy. N Engl J Med 350: 48–58.
45. Funatsu H. Yamashita H. Noma H. Mimura T. Yamashita T. Hori S. (2002) Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133: 70–77.
46. Gaede P. Vedel P. Larsen N. Jensen G. Parving H. Pedersen O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393.
47. Gower E. Cassard S. Chu L. Varma R. Klein R. (2011) Adverse event rates following intravitreal injection of avastin or lucentis for treating age-related macular degeneration [Abstr 6644], 2011 ARVO Annual Meeting, Fort Lauderdale, FL, USA.
48. Gragoudas E. Adamis A. Cunningham E. Jr Feinsod M. Guyer D. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805–2816.
49. Haas L. Maryniuk M. Beck J. Cox C. Duker P. Edwards L. et al. (2012) National standards for diabetes self-management education and support. Diabetes Educ 38: 619–629.
50. He H. Venema V. Gu X. Venema R. Marrero M. Caldwell R. (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274: 25130–25135.
51. Hirai F. Knudtson M. Klein B. Klein R. (2008) Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 145: 700–706.
52. Holash J. Davis S. Papadopoulos N. Croll S. Ho L. Russell M. et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99: 11393–11398.
53. International Diabetes Federation (2011) IDF Diabetes Atlas, 5th edition. Available at: http://www.idf.org/diabetesatlas (accessed 11 October 2012).
54. Ip M. Domalpally A. Hopkins J. Wong P. Ehrlich J. (2012) Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 130: 1145–1152.
55. Javitt J. Aiello L. (1996) Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124: 164–169.
56. Johnson M. (2009) Etiology and treatment of macular edema. Am J Ophthalmol 147: 11–21.
57. Kempen J. O'Colmain B. Leske M. Haffner S. Klein R. Moss S. et al. (2004) The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122: 552–563.
58. Kim I. Ryan A. Rohan R. Amano S. Agular S. Miller J. et al. (1999) Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 40: 2115–2121.
59. Klein R. Klein B. Moss S. Cruickshanks K. (1995) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102: 7–16.
60. Klein R. Klein B. Moss S. Davis M. DeMets D. (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91: 1464–1474.
61. Kohner E. (1972) The natural history of diabetic retinopathy. J R Coll Physicians Lond 6: 259–270.
62. Kohner E. (1991) The natural history of proliferative diabetic retinopathy. Eye (Lond) 5: 222–225.
63. Krebs I. Schmetterer L. Boltz A. Told R. Vécsei-Marlovits V. Egger S. et al. (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97: 266–271.
64. Krzystolik M. Afshari M. Adamis A. Gaudreault J. Gragoudas E. Michaud N. et al. (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120: 338–346.
65. Martin D. Maguire M. Fine S. Ying G. Jaffe G. Grunwald J. et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388–1398.
66. Martin D. Maguire M. Ying G. Grunwald J. Fine S. Jaffe G. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897–1908.
67. Massin P. Bandello F. Garweg J. Hansen L. Harding S. Larsen M. et al. (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399–2405.
68. Michaelides M. Kaines A. Hamilton R. Fraser-Bell S. Rajendram R. Quhill F. et al. (2010) A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117: 1078–1086.
69. Miller J. Adamis A. Shima D. D'Amore P. Moulton R. O'Reilly M. et al. (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574–584.
70. Miller J. Le Couter J. Strauss E. Ferrara N. (2012) Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 120: 106–114.
71. Mitchell P. Bandello F. Schmidt-Erfurth U. Lang G. Massin P. Schlingemann R. et al. (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615–625.
72. Morello C. (2007) Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm 64(17 Suppl. 12): S3–S7.
73. Moss A. (2013) The angiopoietin: Tie 2 interaction: a potential target for future therapies in human vascular disease. Cytokine Growth Factor Rev [ePub ahead of print].
74. Murphy S. Xu J. Kochanek K. and Division of Vital Statistics (2012) Deaths: preliminary data for 2010. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf (accessed 30 October 2013).
75. Nguyen Q. Brown D. Marcus D. Boyer D. Patel S. Feiner L. et al. (2012 a) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119: 789–801.
76. Nguyen Q. Schachar R. Nduaka C. Sperling M. Basile A. Klamerus K. et al. (2012 b) Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 53: 7666–7674.
77. Nguyen Q. Shah S. Heier J. Do D. Lim J. Boyer D. et al. (2009) Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 116: 2175–2181.
78. Nguyen Q. Shah S. Khwaja A. Channa R. Hatef E. Do D. et al. (2010) Two-year outcomes of the ranibizumab for edema of the m Acula in diabetes (READ-2) study. Ophthalmology 117: 2146–2151.
79. Nissen N. Polverini P. Koch A. Volin M. Gamelli R. DiPietro L. (1998) Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152: 1445–1452.
80. Papadopoulos N. Martin J. Ruan Q. Rafique A. Rosconi M. Shi E. et al. (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171–185.
81. Rajendram R. Fraser-Bell S. Kaines A. Michaelides M. Hamilton R. Esposti S. et al. (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130: 972–979.
82. Regeneron (2013) Regeneron and Bayer report positive one-year results from two phase 3 trials of EYLEA® (aflibercept) injection for the treatment of diabetic macular edema. Available at: http://investor.regeneron.com/releasedetail.cfm?ReleaseID=782911 (accessed 12 September 2013).
83. Ryan G. (2007) New pharmacologic approaches to treating diabetic retinopathy. Am J Health Syst Pharm 64(17, Suppl. 12): S15–S21.
84. Santulli R. Kinney W. Ghosh S. Decorte B. Liu L. Tuman R. et al. (2008) Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther 324: 894–901.
85. Shima D. Adamis A. Ferrara N. Yeo K. Yeo T. Allende R. et al. (1995) Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1: 182–193.
86. Soliman A. Silva P. Diala P. Noble J. Cavallerano J. Tolson A. et al. (2011) Awareness of retinopathy and timeliness of follow-up among patients presenting to a diabetes teleophthalmology program, ARVO Annual Meeting, 1–5 May 2011, Fort Lauderdale, FL, USA (abstract 1287/A37).
87. Stefánsson E. (2001) The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 79: 435–440.
88. Steinkuller P. (2010) Legal vision requirements for drivers in the United States. Virtual Mentor 12: 938–940.
89. Stewart M. (2012) Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev 8: 237–246.
90. Stratton I. Aldington S. Taylor D. Adler A. Scanlon P. (2012) A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabetes Care 36: 580–585.
91. Sultan M. Zhou D. Loftus J. Dombi T. Ice K. (2011) A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 118: 1107–1118.
92. Suñer I. Kokame G. Yu E. Ward J. Dolan C. Bressler N. (2009) Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 50: 3629–3635.
93. Thomas G. Rael L. Bar-Or R. Mains C. Slone D. Boyd S. et al. (2012) Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics. Biochem Biophys Res Commun 421: 707–712.
94. Tolentino M. Miller J. Gragoudas E. Chatzistefanou K. Ferrara N. Adamis A. (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114: 964–970.
95. UK Prospective Diabetes Study (UKPDS) Group (1998 a) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853.
96. UK Prospective Diabetes Study Group (1998 b) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703–713.
97. Ulbig M. Hamilton A. (1993) Factors influencing the natural history of diabetic retinopathy. Eye (Lond) 7 (Pt 2): 242–249.
98. White N. Sun W. Cleary P. Danis R. Davis M. Hainsworth D. et al. (2008) Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126: 1707–1715.
99. World Health Organization (2010) Priority eye diseases. Available at: http://www.who.int/blindness/causes/priority/en/index.html (accessed 11 October 2012).
100. Yu L. Liang X. Ferrara N. (2011) Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 408: 276–281.
101. Yuen H. (2012) Factors associated with preventive care practice among adults with diabetes. Prim Care Diabetes 6: 75–78.
102. Zhang P. Zhang X. Brown J. Vistisen D. Sicree R. Shaw J. et al. (2010 a) Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 293–301.
103. Zhang X. Saaddine J. Chou C. Cotch M. Cheng Y. Geiss L. et al. (2010 b) Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 304: 649–656.